What records are connected here?
- Evidence lanes
- 2
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,2,4Evidence: Limited human dataHormones · Sexual and reproductive health
Kisspeptin-10 is a lab-made peptide of ten amino acids, one of a family of kisspeptin peptides that act on reproductive-hormone signalling in the brain. It is not an FDA-approved drug, and FDA reports that no product containing it is approved in any country.1 FDA’s 2024 evaluation found only small, short studies in about 300 people, and insufficient evidence to judge whether it works for low testosterone caused by the brain or pituitary (secondary hypogonadism) in men.1 FDA’s advisory committee voted 11 to 0 against adding it to the list of substances pharmacies may use in compounding. Kisspeptin-10 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6
| What it is | A synthetic ten-amino-acid peptide that activates the kisspeptin receptor (GPR54), which is concentrated in the hypothalamus, according to FDA’s 2024 evaluation.1 |
|---|---|
| FDA status | Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA places it in category 2 of its compounding list, for substances that may present significant safety risks.1,4 |
| Human evidence | Small, short research studies, mostly of single or brief exposures, in about 300 people in total, according to FDA’s evaluation.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Kisspeptin-10 is a synthetic peptide of ten amino acids. FDA reports that kisspeptin was first described in 2001 and kisspeptin-10 in 2004.1
FDA reports that clinics most often promote kisspeptin products for weight loss and fertility, and that some compounding pharmacies reported preparing it.1
FDA’s evaluation states that kisspeptin-10 binds and activates GPR54, the kisspeptin receptor, which is concentrated in the hypothalamus and also found in the pituitary, placenta and pancreas.1
FDA notes that in animal studies the response can fade with continuous exposure, leaving the peptide inactive, and that laboratory findings suggesting it may promote hardening of the arteries are of unclear clinical relevance.1
FDA identified several small studies that together exposed about 300 people, a figure it says may be an overestimate, mostly to single or brief exposures.1
FDA reports that no serious adverse events were described, but that the studies were short, small and often did not report adverse events, and that no published trial tested it on a fixed schedule for more than one day.1
FDA concluded that no meaningful conclusions on effectiveness in men with secondary hypogonadism can be drawn from these studies.1
Evidence-strength label: Limited human data. How this label is assigned
No. FDA’s evaluation, dated July 5, 2024, states that kisspeptin-10 is not a component of an FDA-approved drug and has no United States Pharmacopeia monograph, and that no product containing it is approved in any country.1
None of the sources reviewed here reports an approval of kisspeptin-10 by FDA.1,4
FDA staff evaluated it for the 503A bulks list, the list of substances pharmacies may use in compounding, for secondary hypogonadism in men, and concluded that the balance of criteria weighs against adding it.1
A Federal Register notice announced the October 29, 2024 advisory-committee meeting that discussed kisspeptin-10. According to the minutes, all 11 voting members voted against placing it on the list.2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists kisspeptin-10 in category 2 under the 503A interim policy since September 29, 2023, citing possible immune reactions and limited safety information.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Kisspeptin-10 is not among them.5,6
Whether it helps any condition: FDA found insufficient evidence on effectiveness and no studies by the routes proposed for compounding in men with hypogonadism.1
Its safety with repeated use over weeks or months, which FDA says no published trial has assessed.1
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 15, 2026.1,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Kisspeptin-10: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Kisspeptin-10 are a bounded selection, not every registration or paper about Kisspeptin-10. For the years before Kisspeptin-10 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Kisspeptin-10 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Kisspeptin-10 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; on FDA’s compounding safety-risk list (category 2). FDA staff recommended in 2024 against adding kisspeptin-10 to the 503A compounding list, and FDA places it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; on FDA’s compounding safety-risk list (category 2). FDA staff recommended in 2024 against adding kisspeptin-10 to the 503A compounding list, and FDA places it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 12, 2026
Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights.↗Source date November 12, 2026Literature metadata · added November 15, 2026
Maternal Kisspeptin-10 Treatment Partially Rescues Fetal and Postnatal Cardiac Programming Disrupted by Maternal Hypothyroidism.↗Source date October 16, 2026Literature metadata · added November 15, 2026
Kisspeptin-10 Preserves the Blood-Brain Barrier's Integrity Post-Stroke by Augmenting Claudin-10 Expression.↗Source date June 28, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.
13 of 13 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03771326 at 2026-11-15T22:12:06.897Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was kisspeptin-10.
PubMed lists PMID 18948403 in Endocrinology as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2008-10-23 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 19934405 in American journal of physiology. Endocrinology and metabolism as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-11-24 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
13 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span September 21, 2017 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 42707558 in In silico pharmacology as Journal Article, with publication-date metadata of 2026-09-06 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42726152 in Cardiovascular toxicology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-11 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41022671 in Clinical and experimental pharmacology & physiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-11 (month precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19934405 in American journal of physiology. Endocrinology and metabolism as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-11-24 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23524040 in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences as Journal Article, Research Support, N.I.H., Extramural, Validation Study, with publication-date metadata of 2013-03-04 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40144066 in Journal of veterinary research as Journal Article, with publication-date metadata of 2025-01-31 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22404961 in Reproductive biology and endocrinology : RB&E as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-03-10 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36150474 in General and comparative endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-09-20 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29264460 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2017-10-16 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32045961 in The journal of obstetrics and gynaecology research as Evaluation Study, Journal Article, with publication-date metadata of 2020-02-11 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03771326 at 2026-11-15T22:12:06.897Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was kisspeptin-10.↗
Literature metadata
PubMed lists PMID 18948403 in Endocrinology as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2008-10-23 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register via GovInfo · Official source · Source checked August 21, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026